There are several concrete policy levers a region can apply in order to accelerate the disruption:
Secure domestic manufacturing capacity
Dependence on foreign supply for a technology this consequential to public health and workforce vitality is a strategic vulnerability. Nations should invest in domestic pharmaceutical manufacturing infrastructure for both the active pharmaceutical ingredients and the delivery systems of HOTs.
Adopt open-source development approaches
Open-source modeling platforms, publicly available genomic and proteomic databases, and in-silico drug development methods are democratizing pharmaceutical R&D. Public investment in open-source drug discovery infrastructure could allow nations to bypass proprietary pharmaceutical IP and develop their own HOT formulations without dependence on incumbent firms' pricing and supply decisions.
Use compulsory licensing where necessary
When a drug's value to public health is measured in trillions of dollars annually and its manufacturing cost is under $5 per dose, the case for maintaining monopoly pricing of $1,000+ per month is difficult to sustain. Compulsory licensing, as permitted under the TRIPS Agreement in cases of national health emergency, allows governments to authorize generic production without the patent holder's consent. The WHO's addition of GLP-1s to its Essential Medicines List provides international legitimacy for exactly this kind of policy response.
Frame HOTs as public health infrastructure, not luxury medicine
The policy decisions that most constrain access (coverage restrictions, regulatory caution on off-label use, low public investment in generics research) often reflect an implicit framing of HOTs as optional lifestyle drugs rather than essential health infrastructure. Changing that framing, backed by the economic and social impact data already available, is the precondition for the other policy changes.
Nations that act decisively now capture the compounding benefits earliest. Every year of delay is another year of avoidable obesity-related death, suffering, and economic loss at a scale that, when quantified, is almost incomprehensible.
We are entering a new era of healthcare based on a categorically different kind of medicine whose purpose is not just to save us from illness, but to help us be the best version of ourselves.
The next generation of HOTs will trigger a multi-trillion-dollar global disruption, affecting dozens of industries across multiple sectors, driving a radical global improvement in health and wellness encompassing at least 1 billion people worldwide before 2040.
Optimizing well with advanced HOTs will soon become as important as eating well with nutritious foods. Nations, industries, and individuals that recognize this early and act decisively will be best positioned to capture the extraordinary benefits of this transformation.
Learn more about the HOT disruption and its implications for health, society, and the economy.
Disclaimer
The information provided in this FAQ is for general informational and educational purposes only and is not intended to constitute medical advice, diagnosis, or treatment. This content does not establish a doctor-patient relationship. The content regarding GLP-1 receptor agonists (or any other medical treatments) should not be used as a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment options. Never disregard professional medical advice or delay in seeking it because of something you have read here. The authors and publishers of this FAQ and related report make no representation or warranty, express or implied, regarding the accuracy, adequacy, validity, reliability, availability, or completeness of any information presented. Reliance on any information provided here is solely at your own risk.